FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment

Authorized Users Only
2020
Authors
Jurišić Dukovski, Bisera
Juretić, Marina
Bračko, Danka
Randjelović, Danijela
Savić, Snežana
Crespo Moral, Mario
Diebold, Yolanda
Filipović-Grčić, Jelena
Grigorov, Ivan
Lovrić, Jasmina
Article (Published version)
Metadata
Show full item record
Abstract
Inflammation plays a key role in dry eye disease (DED) affecting millions of people worldwide. Non-steroidal anti-inflammatory drugs (NSAIDs) can be used topically to act on the inflammatory component of DED, but their limited aqueous solubility raises formulation issues. The aim of this study was development and optimization of functional cationic nanoemulsions (NEs) for DED treatment, as a formulation approach to circumvent solubility problems, prolong drug residence at the ocular surface and stabilize the tear film. Ibuprofen was employed as the model NSAID, chitosan as the cationic agent, and lecithin as the anionic surfactant enabling chitosan incorporation. Moreover, lecithin is a mixture of phospholipids including phosphatidylcholine and phosphatidylethanolamine, two constituents of the natural tear film important for its stability. NEs were characterized in terms of droplet size, polydispersity index, zeta-potential, pH, viscosity, osmolarity, surface tension, entrapment effici...ency, stability, sterilizability and in vitro release. NEs mucoadhesive properties were tested rheologically after mixing with mucin dispersion. Biocompatibility was assessed employing 3D HCE-T cell-based model and ex vivo model using porcine corneas. The results of our study pointed out the NE formulation with 0.05% (w/w) chitosan as the lead formulation with physicochemical properties adequate for ophthalmic application, mucoadhesive character and excellent biocompatibility.

Keywords:
Chitosan / Dry eye disease / Lecithin / Nanoemulsion / NSAID
Source:
International Journal of Pharmaceutics, 2020, 576
Publisher:
  • Elsevier B.V.
Funding / projects:
  • Topical nanodelivery systems funded by the University of Zagreb (Z169), the project “Modelling of the Pharmaceutical Spray Drying Process of the Emulsions in Laboratory and Pilot Scale” in collaboration with the industrial partner PLIVA Croatia Ltd.
  • Spanish Government Grant RTI2018-094071-B-C21 (MCIU/AEI/FEDER, UE) (YD and MC-M).

DOI: 10.1016/j.ijpharm.2019.118979

ISSN: 0378-5173

WoS: 000512972500015

Scopus: 2-s2.0-85077471068
[ Google Scholar ]
35
14
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3523
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Jurišić Dukovski, Bisera
AU  - Juretić, Marina
AU  - Bračko, Danka
AU  - Randjelović, Danijela
AU  - Savić, Snežana
AU  - Crespo Moral, Mario
AU  - Diebold, Yolanda
AU  - Filipović-Grčić, Jelena
AU  - Grigorov, Ivan
AU  - Lovrić, Jasmina
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3523
AB  - Inflammation plays a key role in dry eye disease (DED) affecting millions of people worldwide. Non-steroidal anti-inflammatory drugs (NSAIDs) can be used topically to act on the inflammatory component of DED, but their limited aqueous solubility raises formulation issues. The aim of this study was development and optimization of functional cationic nanoemulsions (NEs) for DED treatment, as a formulation approach to circumvent solubility problems, prolong drug residence at the ocular surface and stabilize the tear film. Ibuprofen was employed as the model NSAID, chitosan as the cationic agent, and lecithin as the anionic surfactant enabling chitosan incorporation. Moreover, lecithin is a mixture of phospholipids including phosphatidylcholine and phosphatidylethanolamine, two constituents of the natural tear film important for its stability. NEs were characterized in terms of droplet size, polydispersity index, zeta-potential, pH, viscosity, osmolarity, surface tension, entrapment efficiency, stability, sterilizability and in vitro release. NEs mucoadhesive properties were tested rheologically after mixing with mucin dispersion. Biocompatibility was assessed employing 3D HCE-T cell-based model and ex vivo model using porcine corneas. The results of our study pointed out the NE formulation with 0.05% (w/w) chitosan as the lead formulation with physicochemical properties adequate for ophthalmic application, mucoadhesive character and excellent biocompatibility.
PB  - Elsevier B.V.
T2  - International Journal of Pharmaceutics
T1  - Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment
VL  - 576
DO  - 10.1016/j.ijpharm.2019.118979
ER  - 
@article{
author = "Jurišić Dukovski, Bisera and Juretić, Marina and Bračko, Danka and Randjelović, Danijela and Savić, Snežana and Crespo Moral, Mario and Diebold, Yolanda and Filipović-Grčić, Jelena and Grigorov, Ivan and Lovrić, Jasmina",
year = "2020",
abstract = "Inflammation plays a key role in dry eye disease (DED) affecting millions of people worldwide. Non-steroidal anti-inflammatory drugs (NSAIDs) can be used topically to act on the inflammatory component of DED, but their limited aqueous solubility raises formulation issues. The aim of this study was development and optimization of functional cationic nanoemulsions (NEs) for DED treatment, as a formulation approach to circumvent solubility problems, prolong drug residence at the ocular surface and stabilize the tear film. Ibuprofen was employed as the model NSAID, chitosan as the cationic agent, and lecithin as the anionic surfactant enabling chitosan incorporation. Moreover, lecithin is a mixture of phospholipids including phosphatidylcholine and phosphatidylethanolamine, two constituents of the natural tear film important for its stability. NEs were characterized in terms of droplet size, polydispersity index, zeta-potential, pH, viscosity, osmolarity, surface tension, entrapment efficiency, stability, sterilizability and in vitro release. NEs mucoadhesive properties were tested rheologically after mixing with mucin dispersion. Biocompatibility was assessed employing 3D HCE-T cell-based model and ex vivo model using porcine corneas. The results of our study pointed out the NE formulation with 0.05% (w/w) chitosan as the lead formulation with physicochemical properties adequate for ophthalmic application, mucoadhesive character and excellent biocompatibility.",
publisher = "Elsevier B.V.",
journal = "International Journal of Pharmaceutics",
title = "Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment",
volume = "576",
doi = "10.1016/j.ijpharm.2019.118979"
}
Jurišić Dukovski, B., Juretić, M., Bračko, D., Randjelović, D., Savić, S., Crespo Moral, M., Diebold, Y., Filipović-Grčić, J., Grigorov, I.,& Lovrić, J.. (2020). Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment. in International Journal of Pharmaceutics
Elsevier B.V.., 576.
https://doi.org/10.1016/j.ijpharm.2019.118979
Jurišić Dukovski B, Juretić M, Bračko D, Randjelović D, Savić S, Crespo Moral M, Diebold Y, Filipović-Grčić J, Grigorov I, Lovrić J. Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment. in International Journal of Pharmaceutics. 2020;576.
doi:10.1016/j.ijpharm.2019.118979 .
Jurišić Dukovski, Bisera, Juretić, Marina, Bračko, Danka, Randjelović, Danijela, Savić, Snežana, Crespo Moral, Mario, Diebold, Yolanda, Filipović-Grčić, Jelena, Grigorov, Ivan, Lovrić, Jasmina, "Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment" in International Journal of Pharmaceutics, 576 (2020),
https://doi.org/10.1016/j.ijpharm.2019.118979 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB